STANDARD BIOTOOLS INC.

Standard BioTools Inc. announced a definitive merger agreement with Treeline Biosciences, Inc., an all-stock transaction expected to close in the second half of 2026, with existing shareholders holding approximately 16% of the combined entity. This follows the completed divestment of its SomaScan Business to Illumina, Inc. on January 30, 2026, which generated $388.2 million in net cash and a pre-tax gain of $172.3 million. The company reported a net income of $100.3 million for the six months ended June 30, 2026, primarily driven by the divestment, and significantly increased its cash position.

Standard BioTools Inc. announced its second quarter 2026 financial results, reporting revenue of $20.1 million, a 7.6% decrease year-over-year. Despite the revenue decline, the company achieved an 84% improvement in adjusted EBITDA, narrowing its loss to $2.5 million, and a 1% improvement in operating loss to $25.4 million. The company also confirmed that its merger with Treeline Biosciences is progressing and is expected to close before year-end 2026, leading to the withdrawal of its full-year 2026 revenue outlook.

Standard BioTools Inc. announced its second quarter 2026 financial results, reporting revenue of $20.1 million, a 7.6% decrease year-over-year. Despite the revenue decline, the company achieved an 84% improvement in adjusted EBITDA, reaching a loss of $2.5 million, and a 1% improvement in operating loss, driven by continued cost discipline. The merger with Treeline Biosciences is progressing as planned, with a stockholder vote and closing expected before year-end 2026, leading the company to withdraw its full-year 2026 revenue outlook.

Standard BioTools announced the sale of its Mass Cytometry business to Multiplex Bio for up to $10 million, ensuring continuity of CyTOF and Hyperion product lines. Concurrently, the company received approximately $30 million from Illumina as a buyout for the 2026 earnout and future royalty payments related to the SomaLogic business acquisition. Additionally, the U.S. Federal Trade Commission granted early termination of the waiting period for Standard BioTools' merger with Treeline Biosciences, which is expected to close by year-end 2026, subject to stockholder approval.

Standard BioTools Inc. received a notification from Nasdaq on July 22, 2026, indicating non-compliance with the minimum bid price requirement. The company's share price closed below $1.00 for 30 consecutive business days. Standard BioTools has 180 calendar days, until January 19, 2027, to regain compliance, with no immediate effect on its Nasdaq listing or trading. The company may be eligible for an additional 180-day period if it meets other listing standards and transfers to The Nasdaq Capital Market.

Standard BioTools Inc. announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026. The results will be published after the U.S. market close.

Standard BioTools Inc. announced the filing of a registration statement on Form S-4 with the SEC in connection with its definitive merger agreement with Treeline Biosciences, Inc. The combined company is expected to have over $900 million in cash at closing, funding operations into 2029. Treeline also reported positive headline Phase 1 monotherapy data for TLN-121, showing an 84% overall response rate and 32% complete response rate in relapsed or refractory lymphomas, with no dose-limiting toxicities. Sue Desmond-Hellmann has joined Treeline's Board of Directors.

Standard BioTools Inc. held its 2026 Annual Meeting of Stockholders, where several key proposals were approved. Stockholders voted to approve the 2026 Equity Incentive Plan and an amendment to the 2017 Employee Stock Purchase Plan, increasing shares reserved for issuance by 1,200,000. Additionally, Class I directors Michael Egholm, Thomas Carey, and Eli Casdin were elected, executive compensation was approved on an advisory basis, and PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for 2026.

Standard BioTools Inc. and Treeline Biosciences, Inc. announced a definitive merger agreement to combine in an all-stock transaction. The combined company will operate as Treeline Biosciences and will be led by Treeline's current CEO, Josh Bilenker. The merger is expected to create a well-capitalized biopharma company with over $900 million in cash at closing, providing runway into 2029. Treeline's pipeline includes several clinical-stage programs in oncology, neurology, and immunology, with anticipated data readouts starting in 2027. Standard BioTools will explore strategic options, including divestitures, for its Mass Cytometry and Microfluidics businesses, as Treeline does not intend to operate them. The transaction is expected to close in the second half of 2026.

Standard BioTools Inc. and Treeline Biosciences, Inc. announced a definitive merger agreement in an all-stock transaction. The combined entity, to be named Treeline Biosciences and trade as "TRLN" on Nasdaq, will be led by Treeline CEO Josh Bilenker, MD. It is expected to be well-capitalized with over $900 million in cash at closing, providing a runway into 2029, and will advance a deep pipeline of small molecule inhibitors, protein degraders, and targeted therapy antibody-drug conjugates. Standard BioTools is also exploring strategic options, including divestitures, for its Mass Cytometry and Microfluidics businesses.